Home > Keywords > Thématique > Partenariat

Partenariat

Articles

  • Vect-Horus and Cerimed announce collaboration to support the development of its theragnostic agents
    17 November 2020, by Elodie DORMES

    Vect-Horus is co-developing with Radiomedix one agent which will enter clinical trials in 2021 for the diagnosis of glioblastoma.
    With Cerimed, Vect-Horus also pursues the investigations on its other theragnostic candidates targeting the Low-Density Lipoprotein Receptor, which has been shown to be expressed at high levels in some tumours, including pancreatic tumours.

  • Vect-Horus announces the signing of a scientific collaboration agreement with SERVIER
    28 January 2019, by Jonathan NOWAK

    The two companies intend to enter in a collaboration agreement to develop new therapeutic molecules in the field of central nervous system (CNS) diseases
    VECT-HORUS, a biotechnology company that designs and develops peptide vectors that facilitate the delivery of drugs or imaging agents, notably in the brain, is announcing today the signing of a scientific collaboration agreement with SERVIER. The companies did not disclose the financial terms of this agreement. This collaboration is part (…)

  • Vect-Horus announces the signing of a scientific collaboration agreement with SANOFI in the field of neurodegenerative diseases
    28 January 2019, by Jonathan NOWAK

    The goal of this collaboration is to use VECT-HORUS’ proprietary technology to transport therapeutic antibodies into the brain for the treatment of a neurodegenerative disease.

  • Vect-Horus announces Collaboration and Option Agreement with ASTELLAS Pharma
    4 June 2019, by Jonathan NOWAK

    Vect-Horus announced today the signing of the Research Collaboration and Option Agreement (the “Agreement”) with Astellas Pharma Inc., a Japan based pharmaceutical company (“Astellas”). Vect-Horus will use its proprietary technology VECTrans® to transport Astellas’ antibody to the brain for the treatment of CNS diseases.

  • RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for GBM and PDAC
    19 September 2025, by Emmanuelle BETTENDORF

    Together with our partner Radiomedix, Inc. , we have successfully dosed the first patient in an exploratory Investigational New Drug study evaluating the diagnostic 203Pb-RMX-VH-PIB in Glioblastoma Multiforme (GBM) and Pancreatic ductal adenocarcinoma (PDAC).
    “The initiation of this clinical trial is an important milestone for Vect-Horus and demonstrates continuing progress in the collaboration with our partner RadioMedix,” says Alexandre Tokay, CEO of Vect-Horus.
    “We are looking forward (…)

  • Signature of a Research Common Lab with the Institute for NeuroPhysiopathology (UMR7051 CNRS-AMU)
    28 January 2019, by Jonathan NOWAK

    Since its incorporation in 2005 VECT-HORUS is a leading partner of the French academic institutions CNRS and Aix-Marseille University. Indeed, the company as a spin-off of the NICN (UMR7259 CNRS-AMU) now Institute for NeuroPhysiopathology INP (UMR7051 CNRS-AMU) directed by Dr. Michel KHRESTCHATISKY, cofounder of the company, develops inventions and technologies derived from the “BBB and Neuroinflammation Team”. VECT-HORUS has established a long-term highly efficient collaboration with this (…)

  • Vect-Horus is a partner laureate of the ANR MALZ 2010 call for proposals
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2010 call for proposals and will be involved in the ADHOC project coordinated by the UMR7259 laboratory (Coordinator, Pr. François Féron).
    This project received support (label) from the EUROBIOMED Biocluster.

  • Vect-Horus is a partner laureate of the ANR RPIB Call 2013 for proposals
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) RPIB Call 2013 for proposals and will be involved in the VEC2Brain project involving 3 academic laboratories. The project will be coordinated by Dr Michel Khrestchatisky, Director of the UMR7259 laboratory (CNRS and Aix-Marseille University) and involves the U705 laboratory (Director, Pr. Jean-Michel Scherrmann) of INSERM and the SIMOPRO laboratory (Director Dr. Vincent Dive) of the CEA. This project received (…)

  • Vect-Horus, AAA form scientific collaboration to open new avenues in treatment of brain diseases
    28 January 2019, by Jonathan NOWAK

    The partnership will develop new molecules for the treatment of brain diseases
    Vect-Horus, a French company specialized in the development of vector molecules for the central nervous system, announces today it has signed a scientific collaboration agreement with Advanced Accelerator Applications (AAA), a fast growing international player in Molecular Nuclear Medicine (MNM). The financial terms of the deal have not been disclosed.
    This agreement is part of Vect-Horus’ strategy to leverage (…)

  • Vect-Horus is a partner laureate of the ANR MALZ 2011 call for proposals
    28 January 2019, by Jonathan NOWAK

    VECT-HORUS is a partner laureate of the Agence Nationale de la Recherche (ANR) MALZ 2011 call for proposals and will be involved in the PREVENTAD project coordinated by the UMR7259 laboratory (Coordinator, Dr. Michel Khrestchatisky).
    This project received support (label) from the EUROBIOMED Biocluster.
    VECT-HORUS recruits to reinforce its in vitro BBB model platform.